• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

If You're Buying Clorox, You Aren't Buying Growth

With how much the markets have declined over the past two weeks, I see far better plays out there than Clorox.
By TIMOTHY COLLINS
Feb 28, 2020 | 12:56 PM EST
Stocks quotes in this article: CLX

The action in Clorox (CLX) today, and for the week, has been nuts, but for those buying this name because of the coronavirus and a rising demand for hand sanitizers along with disinfectants, I have to ask why? I do believe we'll see demand, but we're talking about a company with revenue of $1.45 billion last quarter. Will this potential demand really move the needle? And will it last beyond a quarter or two?

Those are the questions you need to answer before buying or considering this name. For me, the answer is no. With the action in the market today it seems Wall Street agrees. Clorox did turn in a strong second quarter with revenue of $1.45 billion and earnings per share hitting $1.46, which was  $0.15 ahead of estimates. Management then guided sales basically flat for the second half of the year. They also updated full-year guidance to a range of $6.10 to $6.25 versus estimates of $6.14. If we factor in the $0.15 beat for Q2, this paints a rather lackluster picture of the second half of the year. Basically, the combination of Q3 and Q4 will come up short of expectations by $0.04 to $0.19. That's not a pretty picture. While a boost in the current quarter sales of sanitizers may help the bottom line a little, that shortfall will require more than a little help.

If you're buying Clorox, you aren't buying growth. You're buying a 2.6% yield along with some stability, but it's not what I would choose to play the coronavirus. We already know that is going to be a high-risk gamble, so as a trader you want to be justly compensated with a high reward potential. Clorox doesn't offer that trade-off.

The action today could be devastating for the strong momentum bulls carried since Thanksgiving. Support of $168 and $164 were sliced like a hot knife through butter. The next area, a very long-trending support line, comes into play at $159. Should bulls recover the $159 to $160 area by close of trade Friday, then a short-term bounce should be in play early next week. It only offers a couple dollar upside, but with a clear stop on the 50-day simple moving average (SMA) at $158, it isn't a horrible risk-reward short-term trading. Unfortunately, the longer-term isn't as optimistic looking as we see the Full Stochastics indicator breaking down and multiple resistance levels now formed against Clorox.

Investors and traders want to define a clear time frame here if getting involved in Clorox along with a clear reason. If that reason is you see this name as a huge winner from the coronavirus, then I'd only take a defined risk trade (i.e., a call or call spread), but if that's the case, then I'd encourage you to try and estimate the amount of market cap it could add to a $21 billion company with $6 billion in sales and no growth. With how much the markets have declined over the past two weeks, I see far better plays out there than Clorox. Other than a one to two day trade next week if this closes over $160 today, I have no interest in owning the name.

(Clorox is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells CLX? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Timothy Collins had no position in the securities mentioned.

TAGS: Investing | Markets | Stocks | Technical Analysis | Trading | Consumer Products | Coronavirus

More from Investing

Let's Take a Closer Look at Zoom Video's Charts

Bruce Kamich
Jan 21, 2021 8:58 AM EST

My gut says to continue to defer purchases of ZM.

Trade Carefully With Soaring Gritstone Oncology

Bruce Kamich
Jan 21, 2021 8:16 AM EST

The history we are concerned about is the past couple of weeks.

Rotation Back to FATMAAN Stocks Provides Strong Market Support

James "Rev Shark" DePorre
Jan 21, 2021 7:20 AM EST

This action indicates that the institutional and big money is afraid of missing out.

The Either/Or Market Strikes Again

Helene Meisler
Jan 21, 2021 6:00 AM EST

Here we go again as big-cap tech rallied and much of the rest sat it out.

Tech Gives Push to Market's Rotation

James "Rev Shark" DePorre
Jan 20, 2021 4:49 PM EST

Money moved back into big-cap technology names, thanks to strong positive reactions to earnings from Netflix.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:35 AM EST GARY BERMAN

    Thursday Morning Fibocall for 1/21/2021

    SPX (Long-Term View) The 1/20/21 NEW high @ 3859...
  • 11:38 AM EST CHRIS VERSACE

    Best Stocks to Buy for the Biden Presidency

    President-elect Biden's massive stimulus plan, int...
  • 08:07 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/20/2021

    SPX (Long-Term View) The 1/8/21 high @ 3826.69 i...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login